Abstract: The invention provides novel compositions based on a structure designated as “Honaucin A”, including Honaucin A variants and analogs, and pharmaceutical compositions, liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these Honaucin A compounds, and variants and analogs thereof are used to ameliorate (including to treat or prevent) inflammation. In one embodiment, these Honaucin A compounds, and variants and analogs thereof are used to ameliorate (including to treat or prevent) inflammation. In one embodiment, these Honaucin A compounds, and variants and analogs thereof are used as bacterial quorumsensing inhibitors. Accordingly, in alternative embodiments the compositions of the invention are used as anti-bacterial agents.

Abstract: Total knee replacements for hinged knee implants include a tibial member, a femoral member, a hinge assembly having a laterally extending axle configured to hingedly attach the femoral member to the tibial member, and a lock mechanism in communication with the hinge assembly. The lock mechanism is configured to (i) lock the femoral member in alignment with the tibial member for a full extension or other defined stabile walking configuration to thereby allow an arthrodesis or stiff knee gait and (ii) unlock to allow the femoral and tibial members to pivot relative to each other for flexion or bending when not ambulating.

Abstract: A bone graft composition includes a biologically-resorbable cement and a plurality of processed bone particles, where each of the bone particles have a shape configured to interconnect with adjacent bone particles. A method for treating a bone defect using the bone graft compositions includes providing the bone graft composition and administering an effective amount of the bone graft composition to a site of a bone defect in a subject. Kits including a biologically-resorbable cement powder and a plurality of processed bone particles are also provided.

Abstract: Disclosed herein are compounds, compositions and methods related to viral inhibition. In some forms, the compounds, compositions and methods are related to binding RNA.

Abstract: Systems and methods for processing image data are provided. A computer implemented method for processing image data, comprises gathering 4-D image data from a subject, extracting time series data, and spatial and degree data of each voxel of the subject, deriving at least one feature from the time series data, deriving at least one feature from the spatial and degree data, combining the at least one feature from the time series data, and the at least one feature from the spatial and degree data to generate combined data, and inputting the combined data to a classifier, wherein the classifier outputs a classification based on the combined data.

Abstract: The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, having the structure:

Abstract: The carrier-envelope phase (CEP) of a laser pulse has been shown to influence many physical processes such as pulse propagation through polar molecules, cross-phase modulation, ponderomotive surface-plasmon electron acceleration, photoemission from metallic surfaces, terahertz emission from the laser breakdown of air, above-threshold ionization, high harmonic generation, and attosecond pulse generation. Current technology does not allow for the CEP stabilization of chirped pulse amplification (CPA) systems operating at a repetition rate much lower than a kHz. The inventors disclose apparatus and methods that enable CEP control in CPA systems operating at arbitrarily-low repetition rates.

Abstract: Pharmaceutical compositions for treating Alzheimer's disease are disclosed. The pharmaceutical compositions include a compound having the general formula: and a pharmaceutically acceptable carrier. Methods for treating Alzheimer's disease, inhibiting ATase I and/or ATase 2, reducing the activity of BACE1, reducing the level of amyloid ?-peptide (A?), and/or reducing the level of APP intracellular domain peptide (AICD) by administering such compositions are also disclosed.

Abstract: A system for creating protected functional descriptions of integrated circuits provides an encrypted functional description that allows the integrated circuit to be simulated with respect to producing outputs for given sets of inputs without identification of the constituent components of the integrated circuit such as the logical gates making up the integrated circuit. The encrypted functional description may include encrypted truth-tables describing the generic gates of the integrated circuit, the encrypted truth-tables securing the function of each logical gate by including multiple redundant table entries mapped to alias values of Boolean logical states and erroneous table entries.

Abstract: The disclosure provided herein provides compositions and methods for producing siRNA. Also disclosed are compositions and methods for modulating the production of siRNA. Also disclosed herein are compositions and methods of treating a disease in a subject comprising administering a Dicer enzyme comprising a helicase domain or a mutated Dicer enzyme to a subject. Also disclosed herein are methods of screening for a candidate modulator that modulates siRNA production.

Abstract: A polymer and a method of forming a polymer are provided. The polymer has the general structure (I): wherein M is an organic moiety; X is a main group element selected from S, P, As, Se, Te, and Sb; R1 is a direct bond between M and the ethylene group depicted between M and X or a hydrocarbyl linking moiety having between 1 and about 9 carbon atoms; R2 is a hydrocarbyl moiety; R3 is an organic linking group; Y has a value of 0, 1, 2, 3, or 4; Z has a value of 0, 1, 2, 3, or 4; YY has a value of 0, 1 or 2; and Y, YY, and Z are such that the total number of moieties bonded to M is 3, 4, 5, or 6.

Abstract: A percutaneous catheter system for use within the human body and an ablation catheter for ablating a selected tissue region within the body of a subject. The percutaneous catheter system can include two catheters thai are operatively coupled to one another by magnetic coupling through a tissue structure. The ablation catheter can include electrodes positioned within a central portion. The ablation catheter is positioned such that the central portion of a flexible shaft at least partially surrounds the selected tissue region. Each electrode of the ablation catheter can be activated independently to apply ablative energy to the selected tissue region. The ablation catheter can employ high impedance structures to change the current density at specific points. Methods of puncturing through a tissue structure using the percutaneous catheter system are disclosed. Also disclosed are methods for ablating a selected tissue region using the ablation catheter.

Abstract: An intercepting device (e.g. a furniture coaster device) is placed under furniture (bed, sofa, chair. etc.), other climable object, or the floor adjacent an object to intercept crawling arthropods and other crawling pests. The intercepting device can be used to monitor the presence of crawling arthropods and other crawling pests (such as bed bugs, ants, cockroaches, beetles, spiders, etc.), reduce pest numbers, and monitor efficacy of pest control procedures. The intercepting device includes pitfall trap surfaces that form multiple pitfall traps.

Abstract: Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.

Abstract: A new approach to the production of coke. In this process multiple optimized value streams are produced from a coke facility located at mine mouth or locally at an existing plant. As part of the process, lower cost Indiana/Illinois Basin-type coals are blended with conventional metallurgical coals. The blending process is optimized to meet coke quality requirements and simultaneously to obtain a pyrolysis gas composition suitable for production of ancillary products including liquid transportation fuels, fertilizer, hydrogen, and electricity. By using lower cost Indiana/Illinois Basin coal it is possible to reduce net coal costs. This process provides a new direction and approach for the production of coke in the future that optimizes value over multiple product streams while reducing both business and technological risk.

Abstract: Methods for culturing the pluripotent stem cells to undergo epithelial-to-mesenchymal transition and for generating high-yield, high-purity cardiomyocyte cultures from pluripotent stem cells are described. Pluripotent stem cells are cultured on a support with an overlaid matrix and, optionally, exposed to one or more factors to induce epithelial-to-mesenchymal transition and cardiogenesis.

Abstract: Described is a method to make liquid chemicals. The method includes deconstructing cellulose to yield a product mixture comprising levulinic acid and formic acid, converting the levulinic acid to ?-valerolactone, and converting the ?-valerolactone to pentanoic acid. Alternatively, the ?-valerolactone can be converted to a mixture of n-butenes. The pentanoic acid can be decarboxylated yield 1-butene or ketonized to yield 5-nonanone. The 5-nonanone can be hydrodeoxygenated to yield nonane, or 5-nonanone can be reduced to yield 5-nonanol. The 5-nonanol can be dehydrated to yield nonene, which can be dimerized to yield a mixture of C9 and C18 olefins, which can be hydrogenated to yield a mixture of alkanes.

Abstract: A method of maximum power point tracking (MPPT) uses an MPPT algorithm to determine a switching frequency for a resonant power converter, including initializing by setting an initial boundary frequency range that is divided into initial frequency sub-ranges bounded by initial frequencies including an initial center frequency and first and second initial bounding frequencies. A first iteration includes measuring initial powers at the initial frequencies to determine a maximum power initial frequency that is used to set a first reduced frequency search range centered or bounded by the maximum power initial frequency including at least a first additional bounding frequency. A second iteration includes calculating first and second center frequencies by averaging adjacent frequent values in the first reduced frequency search range and measuring second power values at the first and second center frequencies. The switching frequency is determined from measured power values including the second power values.

Abstract: A system for measuring an sample includes an illumination source providing electromagnetic radiation pulses at a selected temporal frequency. A microscope focuses the radiation to interact with the sample and produce resultant electromagnetic radiation. A disperser disperses wavelengths of the resultant radiation onto optical sensors, and respective resonant amplifiers amplify signals having the selected temporal frequency. Optical detection apparatus includes the optical sensors, resonant amplifiers, and disperser. The resonant amplifiers amplify portion(s) of their inputs having a selected temporal frequency and attenuate other portion(s).

Abstract: A checkpointing method for creating a file representing a restorable state of a virtual machine in a computing system, comprising identifying processes executing within the virtual machine that may store confidential data, and marking memory pages and files that potentially contain data stored by the identified processes; or providing an application programming interface for marking memory regions and files within the virtual machine that contain confidential data stored by processes; and creating a checkpoint file, by capturing memory pages and files representing a current state of the computing system, which excludes information from all of the marked memory pages and files.